CLIMB BIO, INC. Operating Cash Flow
CLIMB BIO, INC. (CLYM) reported Operating Cash Flow of -$24.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- CLIMB BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$10.55M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$14.38M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.63M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.14M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$54.36M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$15.56M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$20.60M.
- CLIMB BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$37.37M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$24.93M 10-Q · filed 2026-08-06 | -$40.56M derived: sum of 3 quarters · filed 2026-08-06 | -$52.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$14.38M 10-Q · filed 2026-05-07 | -$30.01M derived: sum of 2 quarters · filed 2026-05-07 | -$42.15M derived: sum of 3 quarters · filed 2026-05-07 | -$53.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$15.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$27.77M derived: sum of 2 quarters · filed 2026-03-05 | -$38.92M derived: sum of 3 quarters · filed 2026-08-06 | -$54.36M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$12.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$23.29M derived: sum of 2 quarters · filed 2026-08-06 | -$38.72M 10-Q · filed 2025-11-06 | -$44.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$11.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$26.58M 10-Q · filed 2026-08-06 | -$32.10M derived: sum of 3 quarters · filed 2026-08-06 | -$39.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$15.43M 10-Q · filed 2026-05-07 | -$20.95M derived: sum of 2 quarters · filed 2026-05-07 | -$28.51M derived: sum of 3 quarters · filed 2026-05-07 | -$29.18M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$13.08M derived: sum of 2 quarters · filed 2026-03-05 | -$13.74M derived: sum of 3 quarters · filed 2026-03-05 | -$15.56M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$7.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$8.22M derived: sum of 2 quarters · filed 2025-11-06 | -$10.04M 10-Q · filed 2025-11-06 | -$10.99M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.49M 10-Q · filed 2025-08-12 | -$3.43M derived: sum of 3 quarters · filed 2025-08-12 | $57.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.82M 10-Q · filed 2025-05-14 | -$2.77M derived: sum of 2 quarters · filed 2025-05-14 | $724.00K derived: sum of 3 quarters · filed 2025-05-14 | -$7.24M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$947.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $2.54M derived: sum of 2 quarters · filed 2025-03-25 | -$5.42M derived: sum of 3 quarters · filed 2025-03-25 | -$20.60M 10-K · filed 2025-03-25 |
| 2023-09-30 | $3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$4.47M derived: sum of 2 quarters · filed 2024-11-12 | -$19.65M 10-Q · filed 2024-11-12 | -$28.10M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$7.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$23.14M 10-Q · filed 2024-08-14 | -$31.59M derived: sum of 3 quarters · filed 2024-08-14 | -$35.77M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$15.18M 10-Q · filed 2024-05-15 | -$23.63M derived: sum of 2 quarters · filed 2024-05-15 | -$27.80M derived: sum of 3 quarters · filed 2024-05-15 | -$41.77M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$8.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$12.62M derived: sum of 2 quarters · filed 2024-03-28 | -$26.59M derived: sum of 3 quarters · filed 2024-03-28 | -$37.37M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$18.14M derived: sum of 2 quarters · filed 2023-11-14 | -$28.92M 10-Q · filed 2023-11-14 | -$36.80M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$13.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$24.75M 10-Q · filed 2023-08-10 | -$32.63M derived: sum of 3 quarters · filed 2023-08-10 | -$45.60M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$10.78M 10-Q · filed 2023-05-11 | -$18.66M derived: sum of 2 quarters · filed 2023-05-11 | -$31.63M derived: sum of 3 quarters · filed 2023-05-11 | -$40.11M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$7.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$20.85M derived: sum of 2 quarters · filed 2023-03-06 | -$29.33M derived: sum of 3 quarters · filed 2023-03-06 | -$36.07M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$12.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$21.45M derived: sum of 2 quarters · filed 2022-11-14 | -$28.19M 10-Q · filed 2022-11-14 | -$33.81M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$8.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$15.22M 10-Q · filed 2022-08-15 | -$20.84M derived: sum of 3 quarters · filed 2022-08-15 | -$23.23M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$6.74M 10-Q · filed 2022-05-16 | -$12.36M derived: sum of 2 quarters · filed 2022-05-16 | -$14.74M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$8.01M derived: sum of 2 quarters · filed 2022-03-07 | -$14.10M 10-K · filed 2022-03-07 | |
| 2020-09-30 | -$2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$8.47M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | -$6.09M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |